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Abstract 
Review on chromophobe renal cell carcinoma, with 
data on clinics and cytogenetics. 
Classification 
Chromophobe renal cell carcinoma (ChRCC) is a 
distinct subtype of renal cell carcinoma, possibly 
originating from the the distal nephron. 
Clinics and pathology 
Epidemiology 
ChRCC comprise ~5% of all renal cell carcinomas. 
Most tumors are sporadic, with a slight male 
predilection. 
Pathology 
 ChRCC tumors can vary in size and have a tan to 
brown cut surface. The growth pattern is often solid 
with sheets of cells divided by vascular septae, 
some of which may have perivascular hyalinized 
stroma. ChRCC tumor cells have pale cytoplasm 
and distinct cell membranes.  Small eosinophilic 
cells with granular appearance may be present. 
Nuclei may appear atypical, but are usually small 
with wrinkled nuclear membranes and 
multinucleation (Fig1A).  ChRCC grading is 
complicated by the nuclear atypia, and Fuhrman 
nuclear grading should not be used. Prognosis is 
generally favorable with low grade, low stage 
tumors; but increased cytologic atypia, increased 
mitotic activity, necrosis, and vascular invasion are 
poor prognostic indicators.  Sarcomatoid 
differentiation and high tumor stage are also 
predictors of poor outcome. 
 Special stains and immunohistochemistry can be 
used to distinguish ChRCC from other renal 
epithelial neoplasms.  The presence of Hale's 
colloidal iron in the cytoplasm of tumor cells is 
supportive of ChRCC (an apical staining pattern is 
more supportive of oncocytoma) (Fig.1B). 
Immunohistochemical expression of CK7 (patchy 
to diffuse) combined with the absence of S100A1, 
HNF1beta (nuclear), and CD10 is consistent with a 
ChRCC. 
 Occasionally composite oncocytic tumors with 
features of both oncocytoma and ChRCC tumors 
have been described, and are most commonly seen 
in patients with Birt-Hogg-Dube' syndrome and/or 
oncocytosis. 
Fig. 1A: ChRCC (H&E stain) is comprised of sheets of 
tumor cells with well-defined cell borders, round to 
raisonoid nuclei, and perinuclear halos. Long linear, parallel 
vessels are common in ChRCC. 
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Fig 1B: A Hale's colloidal iron stain is positive (blue) in the 
cytoplasm of ChRCC tumor cells. 
Cytogenetics 
Cytogenetics Morphological 
Chromophobe RCCs generally have a tendency to 
grow very slowly in vitro in comparison to all other 
type of renal tumors. This may be a reason why 
cytogenetic reports are scarce and usually few 
metaphases of poor quality were available for 
investigation. A low chromosome number ranging 
between 32-39, without discernible structural 
changes was the most frequent cytogenetic finding. 
Chromosomes 1, 2, 6, 10, 13, 17 and 21 were most 
frequently lost (Fig.2). Endoreduplication of the 
cells with hypodiploid karyotype has been 
observed. It is of interest, the presence of an 
hypodiploid clone can be disclosed by a DNA index 
of 0.86. The low chromosome number has been 
confirmed by other techniques such as flow 
cytometry, comparative genomic hybridization 
(CGH), restriction fragment length polymorphism 
(RFLP) analysis, and polymorphic microsatellite 
markers. 
Genes involved and 
Proteins 
Note 
High resolution DNA-microarray analysis excluded 
the occurrence of small specific alteration 
confirming that this combination of monosomies 
occurs exclusively in chromophobe subtype of 
RCC. The most commonly mutated genes in 
chRCC are TP53 and PTEN, combined with 
chromosome 17 and 10 deletions (Haake et al 
2016). 
Whole genomes sequencing identified a number of 
genomic rearrangements in the TERT promoter 
region, these same tumors displayed elevated TERT 
gene expression, suggesting a functional role for 
these gene fusions. 





Structural rearrangements in the TERT promoter 
region and TERT upregulation are found in a subset 
of chromophobe RCCs. 
Protein 
Telomerase encodes a catalytic subunit of the 
telomerase enzyme, which functions to maintain 
telomere ends. Telomerase is upregulated in a 
variety of tumors and plays a role tumor cell 
immortalization. 
PTEN (Phosphatase and Tensin 





PTEN mutations are found in approximately 20% 
of chromophobe RCCs1. 
Protein 
PTEN mutations frequently co-occur with loss of 
chromosome 10 resulting in complete loss of 
function. PTEN is a tumor suppressor that functions 
as a protein and lipid phosphatase and negatively 
regulates the PI3K-AKT/PKB signaling pathway. 





Approximately 32% of chromophobe RCCs have a 
TP53 mutation. 
Protein 
TP53 encodes a tumor suppressor protein, which 
plays a regulatory role in many cellular processes 
including DNA repair, growth arrest, apoptosis, 
senescence and metabolism. Mutations in TP53 are 
found in a broad range of tumor types. 
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